Semaglutide Injection 0.25 mg,0.50 mg 5mL

Price range: $85.00 through $360.00

Semaglutide Injection 0.25 mg / 0.50 mg is a prescription GLP-1 receptor agonist product listed in a 5 mL vial presentation. Choose from 1, 2 or 5 vials. The vial volume does not by itself determine the amount to administer; the exact concentration, dose and directions must be confirmed from the product label and prescription. Use only under appropriate medical supervision.

Product at a Glance

Product Detail Information
Active ingredient Semaglutide
Listed strength 0.25 mg / 0.50 mg
Dosage form Injectable formulation / vial presentation
Presentation 5 mL vial
Pack / quantity options 1 vial, 2 vials, 5 vials
Drug class GLP-1 receptor agonist
Prescription / clinical guidance Use only in accordance with applicable prescribing and dispensing requirements
Compare
Add to wishlist
SKU: N/A Categories: ,

Description

What is Semaglutide Injection 0.25 mg / 0.50 mg?


Semaglutide 0.25 mg and 0.50 mg are strengths used in certain injectable semaglutide treatment regimens. Semaglutide acts on GLP-1 receptors involved in blood-glucose regulation, appetite and digestion. The correct dose, concentration and treatment schedule must be taken from the exact prescription and product labeling rather than inferred from vial size.

How Semaglutide Works

Semaglutide is structurally related to the naturally occurring GLP-1 hormone and activates the GLP-1 receptor. In approved uses, this can increase glucose-dependent insulin secretion, reduce glucagon when glucose is elevated, slow gastric emptying and influence appetite and satiety.

Understanding the 5 mL Vial Presentation

“5 mL” describes the listed vial volume, not an individual dose. The concentration of semaglutide in the vial and the amount prescribed determine administration. Never calculate a dose from vial volume alone.

Administration and Storage

Follow the dispensing label and the instructions supplied with the exact product. Do not use generic online dosing instructions to calculate an injection. Storage conditions can vary by formulation; verify temperature, light protection, beyond-use/expiration date and handling requirements on the actual packaging. Do not use a product that has been frozen, damaged, contaminated, improperly stored or expired.

Important Safety Information

Semaglutide is a GLP-1 receptor agonist and is not appropriate for every patient. Approved semaglutide products carry important warnings and contraindications. A healthcare professional should review the patient’s medical history, current medicines and treatment goals before use.

Common adverse reactions reported with approved semaglutide products are mainly gastrointestinal and can include nausea, vomiting, diarrhea, abdominal pain and constipation. Serious reactions can also occur, including pancreatitis, gallbladder problems, kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions and complications of diabetic retinopathy in some patients.

Approved semaglutide labeling includes a boxed warning concerning the risk of thyroid C-cell tumors observed in rodents. Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of the rodent findings to humans has not been established.

Tell your healthcare professional about planned surgery or procedures requiring general anesthesia or deep sedation, and discuss pregnancy or plans for pregnancy. This summary is not a substitute for the complete prescribing information for the exact product supplied.

5. Who Should Speak With a Healthcare Professional Before Use?

  • Anyone considering semaglutide should have the exact product, indication and dose assessed by a qualified healthcare professional.
  • Discuss a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, previous pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease, diabetic retinopathy and serious allergies.
  • Tell the prescriber about insulin, sulfonylureas and other medicines that can affect blood glucose, as well as other oral medicines when using oral semaglutide.
  • Discuss pregnancy, plans for pregnancy or breastfeeding before treatment. Current FDA labeling advises discontinuation of semaglutide at least 2 months before a planned pregnancy because of its long washout period.
  • Tell healthcare providers about semaglutide before planned surgery or deep sedation because GLP-1 receptor agonists delay gastric emptying and pulmonary aspiration has been reported.

The information on this page is provided for general educational and product-information purposes and is not medical advice, diagnosis or a substitute for the prescribing information supplied with the medication. Semaglutide is a prescription medicine and may not be appropriate for everyone. Always follow the exact product label and instructions from a licensed healthcare professional. Seek urgent medical care for a suspected medical emergency.

Additional information

PACK SIZE

1 Vial, 2 Vial, 5 Vial

1 review for Semaglutide Injection 0.25 mg,0.50 mg 5mL

  1. Carry (store manager) –

    I’m happy with this product and found it helpful. The overall experience was good, and I’m satisfied with my purchase. I would recommend it based on my experience.

    Carry
Add a review

Your email address will not be published. Required fields are marked *

FAQs

What is semaglutide 0.25 mg / 0.50 mg injection?
It is an injectable semaglutide presentation listing 0.25 mg and 0.50 mg strengths. Semaglutide is a GLP-1 receptor agonist. The exact indication and directions depend on the specific prescribed product.
Is 0.25 mg the same as 0.50 mg?
No. They are different amounts of semaglutide. Do not change from one strength to another unless your prescriber instructs you to do so.
Does a 5 mL vial mean I inject 5 mL?
No. 5 mL describes the vial presentation. It does not establish an injection volume or dose. Use only the concentration and administration instructions on the exact prescription label.
How often is injectable semaglutide used?
Some approved injectable semaglutide products are administered once weekly, but you must follow the schedule for the exact medication prescribed to you.
Is semaglutide insulin?
No. Semaglutide is a GLP-1 receptor agonist; it is not insulin.
What are common semaglutide side effects?
Common adverse reactions with approved semaglutide products include nausea, vomiting, diarrhea, abdominal pain and constipation. Review the exact product labeling for the complete safety information.

Related products